4′-DMA-7,8-DHF
Eutropoflavin · 4′-Dimethylamino-7 · 8-dihydroxyflavone · 4′-DMA-DHF · R7
Last updated
At a glance
Overview
4′-DMA-7,8-DHF — sold under the trade name Eutropoflavin — is the most potent orally active TrkB agonist characterized in the published literature, engineered from the 7,8-dihydroxyflavone scaffold by the Ye lab at Emory to mimic what BDNF does at its own receptor. For the nootropics-leaning corner of the looksmaxxing and longevity community, that mechanism is the entire pitch: a small molecule that crosses the blood–brain barrier, drives PI3K/Akt and MAPK/ERK downstream of TrkB, and produces measurable hippocampal neurogenesis on a 2–3 week timeline.
The community uses it for three overlapping goals — mood and anhedonia support, baseline cognitive sharpening, and long-arc neuroprotection — and it earned its niche by doing all three from a single 10 mg morning capsule without touching dopamine, the HPTA, or any of the receptor systems that make stimulant nootropics feel brittle. It is hormonally inert, requires no PCT, and stacks cleanly on top of creatine, omega-3, choline donors, and Polygala for users building a neurotrophic base under a larger physique or longevity protocol.
"4′-DMA-7,8-DHF exhibited the most potent TrkB agonistic activity in vitro and displayed robust antidepressant-like effects in mice after oral administration." — Liu et al., J. Med. Chem. (2010)
The sections below cover the documented dose ladder, the PK rationale for once- versus twice-daily administration, the specific stacks that have converged around Eutropoflavin in r/NootropicsDepot, the side-effect profile at the 10–30 mg/day window, and the contraindications — pregnancy, lactation, and active TrkB-implicated malignancy — that the literature flags plainly.
How 4′-DMA-7,8-DHF works
TrkB Receptor Agonism — The Primary Lever#
4′-DMA-7,8-DHF is a small-molecule agonist of tropomyosin receptor kinase B (TrkB) — the same receptor activated by endogenous brain-derived neurotrophic factor (BDNF). The dimethylamino substitution at the 4′-position of the B-ring on the parent 7,8-dihydroxyflavone scaffold was selected from an extensive SAR screen at the Ye lab and produces tighter receptor binding and longer-duration activation than the parent flavone.
Receptor engagement triggers TrkB autophosphorylation and the canonical downstream cascades — PI3K/Akt (pro-survival, anti-apoptotic) and MAPK/ERK (synaptic plasticity, CREB transcription). The practical readout: the molecule pharmacologically mimics chronic BDNF tone without requiring exercise- or stress-driven endogenous release.
"4′-DMA-7,8-DHF exhibited the most potent TrkB agonistic activity in vitro and displayed robust antidepressant-like effects in mice after oral administration." — Liu X. et al., Journal of Medicinal Chemistry, 2010
Sustained Central Activation Despite Low Plasma Exposure#
The pharmacokinetic profile is unusual and worth understanding. Plasma Cmax for 4′-DMA-7,8-DHF is actually lower than the parent 7,8-DHF, yet brain TrkB phosphorylation is stronger and longer-lasting. This is the practical justification for the small (10–20 mg) oral doses used in the community — receptor pharmacodynamics, not plasma concentration, drive the effect.
"Cmax value of 4′-DMA-7,8-DHF in rat plasma was found to be lower than 7,8-DHF (8 ng/mL vs 48 ng/mL), yet it induced a greater and more sustained TrkB phosphorylation signal in brain tissue." — Karakaya M.F. et al., Current Pharmaceutical Analysis, 2023
The molecule is orally bioavailable, crosses the blood-brain barrier, and undergoes phase II conjugation including O-methylation — and importantly, the O-methylated metabolite retains TrkB activity, extending the effective pharmacodynamic window past what the parent half-life would predict.
"The pharmacokinetic profile of 7,8-DHF and derivatives includes oral bioavailability and brain penetration, with phase II metabolism yielding active O-methylated metabolites." — Liu C., Chan C.B., Ye K., Neuropharmacology, 2013
This is why morning dosing covers a full cognitive workday and why the 5-on / 2-off cycling some users adopt is precautionary rather than mechanism-driven — receptor signal trough-clamps high enough on continuous low doses to avoid desensitization at standard tiers.
Hippocampal Neurogenesis and Synaptic Plasticity#
Chronic TrkB activation in the dentate gyrus drives proliferation of neural progenitors — the same endpoint targeted by SSRIs, but reached via direct receptor agonism rather than serotonergic detour. In the foundational rodent work, 21 days of oral dosing produced significantly increased BrdU⁺ progenitor counts and behavioral antidepressant effects comparable to or exceeding standard reference compounds.
This is the mechanism behind the 2–3 week onset window community users report for mood and motivation effects. The acute "lift" some responders feel on day one is direct receptor engagement; the durable shift in baseline cognition and affect requires chronic dosing to translate TrkB signal into measurable hippocampal remodeling. For the looksmaxxing- and longevity-focused reader, this is the same axis adaptogens like Polygala tenuifolia and Lion's Mane nibble at — 4′-DMA-7,8-DHF just hits it directly.
Anti-Apoptotic Neuroprotection#
TrkB → Akt signaling is one of the most robust anti-apoptotic pathways in the central nervous system. In T48 cells stably expressing TrkB, 4′-DMA-7,8-DHF protected against staurosporine-induced apoptosis more potently than the parent 7,8-DHF. The broader 7,8-DHF scaffold has rodent data in models of TBI, stroke, and neurodegeneration.
The translational case to human concussion or impact-sport recovery has not been made in published clinical work — but the mechanism is the rationale community users running contact-sport or heavy-volume training blocks reach for the compound during high-stress phases. Treat this as mechanism-driven, not outcome-validated.
PDXP Inhibition and Vitamin B6 Bioavailability#
A more recently characterized off-target action of the parent scaffold is direct inhibition of pyridoxal-5′-phosphate phosphatase (PDXP), the enzyme that degrades active vitamin B6 (PLP) in neurons. Inhibiting PDXP raises intracellular PLP, which is a cofactor for the synthesis of GABA, serotonin, dopamine, and glycine.
"7,8-DHF directly targets and inhibits PDXP with an IC50 of 3.6 μM, increasing cellular PLP availability and potentially modulating B6-dependent neural processes." — Brenner M. et al., eLife, 2024
Whether 4′-DMA-7,8-DHF fully retains this PDXP activity has not been formally characterized, but the structural similarity makes it plausible. Practical implication: keeping a basic B-complex in the stack ensures cofactor availability is not the rate-limiting step on whatever PDXP-mediated PLP increase the compound is producing.
Tying It Together#
| Mechanism | Downstream Effect | Practical Outcome |
|---|---|---|
| TrkB agonism → PI3K/Akt, MAPK/ERK | CREB-driven transcription, synaptic plasticity | Mood lift, motivation, learning |
| Sustained central TrkB phosphorylation | Long pharmacodynamic window despite short plasma t½ | Once-daily AM dosing covers the workday |
| Hippocampal neurogenesis | Dentate gyrus progenitor proliferation | Durable mood and cognition shift at 2–3 weeks |
| Anti-apoptotic Akt signaling | Neuroprotection against oxidative and excitotoxic insult | Mechanism-driven adjunct during high-stress training blocks |
| PDXP inhibition (scaffold-level) | Elevated neuronal PLP, B6-dependent neurotransmitter synthesis | Synergy with B-complex cofactors in the stack |
The clean summary: 4′-DMA-7,8-DHF is a BDNF mimetic with better drug-like properties than BDNF itself — orally active, brain-penetrant, and pharmacologically tuned for sustained TrkB engagement at sub-30 mg doses. It is hormonally inert, requires no ancillaries or PCT, and slots cleanly into mood, cognition, neurogenesis, and longevity protocols without interfering with anabolic, hair, or sexual stacks running alongside.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 10–10 mg | Once daily | Documented entry-level range |
| Mid | 10–20 mg | Once daily | Most commonly studied range |
| High | 20–30 mg | Once daily | Morning dosing is the default to avoid sleep disruption. Twice-daily (AM + early afternoon) at the 20mg/day tier; afternoon doses are kept before 2 PM to preserve sleep architecture. |
Cycle length & outcomes
Documented cycle
4–12 weeks
Plateau after
8 wks
4′-DMA-7,8-DHF is a small-molecule TrkB agonist, not a hormone — there is no HPTA suppression, no receptor crash, and no PCT. Cycle design is built around two practical realities: the chronic onset window for neurogenesis and mood effects (~2–3 weeks of consistent dosing), and the community-level concern about TrkB downregulation with continuous high-dose exposure.
Cycle Length by Goal#
| Goal | Cycle Length | Daily Dose | Split |
|---|---|---|---|
| Cognitive baseline / longevity stack | 8–12 weeks, continuous | 10 mg | 1× AM |
| Mood / anhedonia support | 4–8 weeks | 20 mg | 10 mg AM + 10 mg early PM |
| Neurogenesis / skill acquisition | 6–8 weeks | 20 mg | 10 mg AM + 10 mg early PM |
| Heavy training / contact-sport neuroprotection | Run with the training block | 10 mg | 1× AM |
| Stimulant-stack adjunct (modafinil, racetams) | As-needed, daily | 10 mg | 1× AM |
| Advanced / responder-tuned | 4–6 weeks max | 20–30 mg | 2× before 2 PM |
The 10 mg/day tier is the workhorse protocol and corresponds to the Nootropics Depot capsule format that defined community dosing from 2020 onward.
"The most common protocol for Eutropoflavin is 10 mg once daily, with users reporting benefits to cognitive baseline, mood, and motivation over several weeks." — Nootropics Depot Product Page (2020)
Doses above 30 mg/day are not supported by any published rationale, produce diminishing returns at the receptor, and shift the side-effect profile toward headache and over-stimulation.
Onset Timing#
This is not an acute compound for most subjects. Expect a two-track response:
- Acute (day 1–7): A subset of responders report a same-day "lift" — sharper focus, mild mood elevation, more vivid dreaming. This is consistent with rapid TrkB phosphorylation observed in brain tissue after single oral doses in rodents.
- Chronic (week 2–4): The neurogenesis and durable mood effects emerge here. The 2010 Emory work demonstrated significant dentate-gyrus BrdU⁺ progenitor expansion after 21 days of chronic 5 mg/kg oral dosing in mice, mirroring the onset curve of SSRIs.
"4′-DMA-7,8-DHF exhibited the most potent TrkB agonistic activity in vitro and displayed robust antidepressant-like effects in mice after oral administration." — Liu et al., Journal of Medicinal Chemistry (2010)
The PK explains the chronic-dominant profile: plasma exposure is modest, but receptor-level pharmacodynamics outlast plasma half-life.
"Cmax value of 4′-DMA-7,8-DHF in rat plasma was found to be lower than 7,8-DHF (8 ng/mL vs 48 ng/mL), yet it induced a greater and more sustained TrkB phosphorylation signal in brain tissue." — Karakaya et al., Current Pharmaceutical Analysis (2023)
Translation: chasing higher plasma peaks with bigger single doses is the wrong lever. Steady trough exposure via once- or twice-daily dosing is what produces results.
Loading and Tapering#
No loading phase is required or useful. The compound's effects are gated by chronic TrkB activation, not by a tissue saturation curve. A 30 mg "front-load" the first week does not accelerate the neurogenesis timeline and tends to produce headache.
No taper is required. TrkB is not a hormone-axis receptor; discontinuation produces no rebound and no withdrawal phenotype. Effects gradually fade over 2–4 weeks post-cycle as BDNF-driven structural changes normalize.
On-Cycle Monitoring#
Routine bloodwork is not specifically indicated for this compound. It is hormonally inert — no impact on lipids, hematocrit, liver enzymes, or the HPTA. Subjects already running quarterly bloodwork as part of a broader physique stack should continue that cadence; nothing needs to change because of 4′-DMA-7,8-DHF.
The two things worth tracking subjectively:
- Sleep quality and dream intensity — TrkB modulation alters REM architecture. Vivid dreaming is normal; insomnia signals the afternoon dose is too late.
- Headache and over-stimulation at the 20–30 mg tier — these are the dose-limiting symptoms and the cue to drop back to 10–20 mg.
Cycling Pattern: Continuous vs. Pulsed#
The community is split into two camps:
- Continuous daily (modal pattern): 10 mg/day, indefinitely. No published evidence of receptor desensitization at this dose. This is the default for users running it as a longevity / cognitive baseline agent.
- 5-on / 2-off or 6-weeks-on / 2-weeks-off: Preferred by users who want to hedge against TrkB downregulation, particularly at the 20 mg/day tier. The 2-week washout is empirically chosen, not validated.
For the 20–30 mg/day advanced protocol, a 6–8 week cycle followed by a 2-week off period is the prudent default. The lower 10 mg/day protocol can be run continuously without concern.
Stack Timing Notes#
- Polygala tenuifolia — co-dosed AM; the dominant "BDNF stack" pairing in the community.
- Choline donors (alpha-GPC, CDP-choline) — co-dosed AM, supports the synaptic remodeling thesis.
- Creatine 5 g + omega-3 (EPA-dominant) — daily, timing-flexible; the baseline mood-and-cognition foundation.
- Stimulant nootropics (modafinil, racetams) — 4′-DMA-7,8-DHF goes in first thing AM, stimulant layered on top. Titrate the stimulant down initially — the stack potentiates focus and the usual dose may feel sharper.
- Late-day stimulants of any kind — avoid stacking with a PM dose of 4′-DMA-7,8-DHF; the combined sleep cost is not worth it.
Run at 10 mg AM for the first two weeks, evaluate response, and only escalate to a split 20 mg/day protocol if the chronic-window effects are underwhelming. Most subjects do not need more than that.
Risks & mistakes
Common (most users)#
- Headache — the most frequently reported effect, typically at 20mg+ daily or when doses stack late in the day. Mitigation: drop back to 10mg once-daily, increase hydration, and ensure electrolyte intake is adequate. Most users find headaches resolve within 3–5 days of dose reduction.
- Vivid dreaming / lighter sleep — consistent with TrkB modulation of REM architecture. Not inherently problematic, but disruptive if dosed late. Mitigation: anchor the dose to morning, with any second dose taken before 2 PM.
- Mild stimulation / "wired" feeling — front-loaded in the first week. Usually settles as receptor signaling normalizes. Pairs poorly with high-dose caffeine or modafinil during titration; back the stimulant base down for the first 7–10 days.
- GI upset (mild nausea, loose stool) — the flavone scaffold is not gut-friendly on an empty stomach. Mitigation: administer with a small fat-containing meal. Bioavailability is not meaningfully impaired by food.
- Slow onset of mood effects — not a side effect per se, but a common complaint. The antidepressant-like and neurogenesis effects in the published rodent work emerged after 14–21 days of chronic dosing (Liu 2010). Expectations should be calibrated accordingly.
"4′-DMA-7,8-DHF exhibited the most potent TrkB agonistic activity in vitro and displayed robust antidepressant-like effects in mice after oral administration." — Liu et al., J. Med. Chem. 2010
Uncommon (dose-dependent or individual)#
- Anxiety / agitation — a minority of responders experience the opposite of the expected anxiolytic phenotype, particularly when stacked with stimulants or in users with baseline anxiety disorders. If the agitation phenotype appears, drop to 10mg AM only or discontinue; it generally does not resolve by pushing through.
- Insomnia — almost always tied to late-day dosing. Move the entire dose to pre-noon. If insomnia persists on AM-only dosing, the compound is likely a non-fit for that individual.
- Over-stimulation at 30mg+ — reported in community threads at the upper end of the dose range. The dose–response curve plateaus well before 30mg/day for most users; pushing past 20mg/day rarely buys additional benefit and reliably buys side effects.
- Mood blunting on chronic high-dose use — a small subset of long-term users report emotional flattening after 8+ weeks of continuous 20mg+ dosing, plausibly reflecting TrkB downregulation. A 2-week washout typically restores baseline; cycling 6-on / 2-off mitigates this.
- Headache that does not resolve with dose reduction — uncommon but real. Discontinue and reassess; do not push through.
Rare but serious#
- Severe persistent headache, visual disturbance, or focal neurological signs — no causal link is established, but any new neurological symptom on a TrkB agonist warrants immediate discontinuation and medical evaluation.
- Theoretical tumor-promotion risk. TrkB signaling is implicated in the aggressiveness of several cancer cell lines (neuroblastoma, certain breast and pancreatic phenotypes). No human cases link 4′-DMA-7,8-DHF or the parent 7,8-DHF scaffold to neoplasia, but the mechanistic concern is real enough that chronic high-dose TrkB agonism is not appropriate for subjects with active or recent malignancy.
- Allergic / hypersensitivity reaction — rare, generic to any orally administered novel small molecule. Discontinue at first sign of rash, swelling, or respiratory symptoms.
Hard contraindications#
- Pregnancy and lactation — no safety data exist. The compound crosses the blood–brain barrier and modulates a developmentally critical neurotrophin axis. Absolute exclusion.
- Active malignancy, particularly neuroblastoma or any TrkB-expressing tumor — TrkB agonism is mechanistically contraindicated. This is not a hedge; it is a known oncogenic signaling axis.
- Personal or strong family history of neuroblastoma or TrkB-driven cancers — same rationale, applied conservatively.
- Concurrent investigational TrkB modulators (e.g. LM22A-4, other 7,8-DHF derivatives) — no interaction data; mechanism overlap means additive receptor occupancy with no upside.
- Late-day dosing — not a medical contraindication but a protocol-level one. Doses after early afternoon reliably disrupt sleep architecture and erode the cognitive benefit the compound is being administered for in the first place.
Gender, hormonal, and PCT considerations#
4′-DMA-7,8-DHF is hormonally inert. It does not interact with the HPTA, androgen receptors, estrogen receptors, or the GH/IGF-1 axis. There is no aromatization, no virilization risk, no suppression, and no PCT requirement. Dosing is identical across the subject pool — bodyweight-independent and sex-independent — which makes it one of the cleaner nootropics to slot into a stack alongside AAS, SARMs, or peptide protocols without confounding endocrine bloodwork.
The only sex-specific consideration is pregnancy and lactation, both of which are hard exclusions. Routine cycle bloodwork is not indicated for this compound in isolation; it should be monitored as part of whatever broader physique or longevity stack it sits inside.
FAQ — 4′-DMA-7,8-DHF
Research & citations
5 studies cited on this page.
Conclusion
4′-DMA-7,8-DHF stands out as a high-affinity, orally bioavailable TrkB agonist for research targeting cognitive enhancement, mood support, and neuroprotection — especially where BDNF/TrkB signaling is the goal. Proper protocol design is key, given its steep dose-response and timing sensitivity.
Key takeaways:
- Standard protocol: 10 mg orally, once daily in the morning
- Intermediate/intensive protocols: 10 mg twice daily (AM + early afternoon), total 20 mg
- Cycle duration: 4–12 weeks; continuous daily administration is typical, with 5-on/2-off cycling as an option
- Avoid late-day dosing — morning/early afternoon keeps sleep architecture intact
- Stacking: Synergizes well with Polygala tenuifolia, choline donors, creatine, omega-3, and basic B-vitamin support
- Headline benefit: Robust TrkB activation for chronic cognitive, mood, and neuroprotective effects backed by strong preclinical data
- Hard exclusions: pregnancy, lactation, active malignancy, or late-day dosing
For experiments in neuroplasticity, mood, or cognitive baseline, 4′-DMA-7,8-DHF provides a well-tolerated, mechanism-driven option with a decade of positive community experience and substantial preclinical foundation (Liu 2010; Karakaya 2023).